Drugs / BTH1704
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02132403 | Aug 2014 → Apr 2015 | malignant pancreatic neoplasm | University of Illinois at Chicago | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BTH1704 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02132403 ↗ |
| Modality | Monoclonal antibody | “BTH1704, a monoclonal antibody that targets an aberrantly glycosylated antigen Mucin 1” NCT02132403 ↗ |
| Target | MUC1 | “a monoclonal antibody that targets an aberrantly glycosylated antigen Mucin 1” NCT02132403 ↗ |